News
-
-
-
PRESS RELEASE
Transgene présente des données précliniques de son vaccin innovant contre le mpox produit sur lignée cellulaire, TG-MVA
Transgene présente des données précliniques prometteuses de son vaccin innovant contre le mpox, basé sur MVA et produit sur lignée cellulaire, au World Congress on Infectious Diseases. Potentiel d'approvisionnement global en vaccins -
PRESS RELEASE
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line–Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
Transgene to present positive preclinical data on TG-MVATM vaccine candidate against Mpox at WCID 2026. The cell-line based vaccine offers robust protection with scalable manufacturing -
-
-
PRESS RELEASE
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
Transgene expands myvac® into Non-Small Cell Lung Cancer with TG4070, an individualized neoantigen therapeutic vaccine. New randomized Phase 1 trial in NSCLC announced, combining innovative technologies for faster vaccine supply -
-
-
PRESS RELEASE
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
Transgene to present preclinical data on novel TG-MVA prophylactic vaccine against mpox at World Congress on Infectious Diseases. Focus on Orthopoxvirus-related diseases. Oral presentation by Head of Vectorology Laboratory, Nathalie Silvestre
